skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Cancer Research remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

GARRETT, Joan T ; SUTTON, Cammie R ; KURUPI, Richard ; BIALUCHA, Carl Uli ; ETTENBERG, Seth A ; COLLINS, Scott D ; QING SHENG ; WALLWEBER, Jerry ; DEFAZIO-ELI, Lisa ; ARTEAGA, Carlos L

Cancer research (Chicago, Ill.), 2013-10, Vol.73 (19), p.6013-6023 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
2
Inhibition of angiogenesis by antiestrogens
Inhibition of angiogenesis by antiestrogens
Material Type:
Artigo 		Adicionar ao Meu Espaço

Inhibition of angiogenesis by antiestrogens

GAGLIARDI, A ; COLLINS, D. C

Cancer research (Chicago, Ill.), 1993-02, Vol.53 (3), p.533-535 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
3
INHIBITION OF ANGIOGENESIS BY SURAMIN
INHIBITION OF ANGIOGENESIS BY SURAMIN
Material Type:
Artigo 		Adicionar ao Meu Espaço

INHIBITION OF ANGIOGENESIS BY SURAMIN

GAGLIARDI, A ; HADD, H ; COLLINS, DC

Cancer research (Chicago, Ill.), 1992-09, Vol.52 (18), p.5073-5075 [Periódico revisado por pares]

PHILADELPHIA: Amer Assoc Cancer Research

Texto completo disponível

Citações Citado por
4
Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial
Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial

Bialucha, Carl U. ; Collins, Scott D. ; Shim, Yeonju ; Zhang, Xiamei ; Velazquez, Roberto ; Kowal, Colleen ; Bullock, Caroline ; Cai, Hongbo ; Rivera, Stacy M. ; Goldovitz, Julie M. ; Kurth, Esther ; Loo, Alice T. ; Yang, Guizhi ; Green, John ; Ostrom, Lance ; Meyer, Matthew J. ; Mosher, Rebecca ; Gao, Hui ; Williams, Juliet ; Lees, Emma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.872-872 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Abstract P5-05-06: Cobalamin metabolism in breast cancer
Abstract P5-05-06: Cobalamin metabolism in breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P5-05-06: Cobalamin metabolism in breast cancer

Collins, DA

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-05-06 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Abstract OT3-02-03: An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
Abstract OT3-02-03: An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract OT3-02-03: An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer

Lyons, T ; Mallet, V ; Collins, D ; Malone, E ; Milewski, M ; Egan, K ; Hennessy, B ; Grogan, L ; Breathnach, O ; Morris, P

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT3-02-03-OT3-02-03 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines
Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines

Collins, DM ; Gaynor, N ; Conlon, N ; Gullo, G ; Eustace, AJ ; Crown, J

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-07-08 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Abstract P4-06-19: The effect of relieving adenosine-mediated immunosuppression on trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) against HER2+ breast cancer cell lines
Abstract P4-06-19: The effect of relieving adenosine-mediated immunosuppression on trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) against HER2+ breast cancer cell lines
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P4-06-19: The effect of relieving adenosine-mediated immunosuppression on trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) against HER2+ breast cancer cell lines

Gaynor, N ; Noone, J ; Monedero, J ; Murphy, EE ; O'Gorman, DJ ; Crown, J ; Collins, DM

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-06-19 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer
Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer

Conlon, N ; McDermott, M ; Browne, B ; Roche, S ; O'Neill, F ; Meiller, J ; Browne, A ; Eustace, A ; Collins, DM ; O'Donovan, N ; Crown, J

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-03-02 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Duvall, Jeremy R. ; Bukhalid, Raghida A. ; Cetinbas, Naniye M. ; Catcott, Kalli C. ; Slocum, Kelly ; Avocetien, Kenneth ; Bentley, Keith W. ; Bradley, Stephen ; Clardy, Susan ; Collins, Scott D. ; Ditty, Elizabeth ; Eitas, Timothy ; Jones, Brian D. ; Kelleher, Eugene W. ; Lee, Winnie ; Monnell, Travis ; Mosher, Rebecca ; Protopopova, Marina ; Qin, LiuLiang ; Shaw, Pamela ; Ter-Ovanesyan, Elena ; Thomas, Joshua D. ; Wongthida, Phonphimon ; Xu, Ling ; Yang, Liping ; Zurita, Jeffrey ; Toader, Dorin ; Damelin, Marc ; Lowinger, Timothy B.

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1738-1738 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de1985  (13)
  2. 1985Até1992  (24)
  3. 1993Até2002  (19)
  4. 2003Até2013  (38)
  5. Após 2013  (63)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.